Tuesday, February 21, 2006

Chronic Diseases and Premium-Priced Devices Driving the US Vascular Access Device Market

Chronic Diseases and Premium-Priced Devices Driving the US Vascular Access Device Market

According to a new report entitled US Markets for Vascular Access Devices 2006, the US vascular access device market generated almost $1.1 billion in revenues in 2005 and will grown over 5% annually over the next five years.

Waltham, MA (PRWEB) September 11, 2006

Millennium Research Group (MRG), the global authority on medical technology market intelligence, finds that the US vascular access device market (which includes short peripheral intravenous catheters, central venous catheters (CVCs), peripherally inserted central catheters (PICCs), dialysis catheters, and implantable ports) will be driven by chronic diseases like end-stage renal disease (ESRD) and cancer. The increasing over-65 cohort in the US is expected to expand the number of people susceptible to chronic illness. Because the treatment of chronically ill patients often employs vascular access therapies, vascular access device unit sales will grow in tandem with the growth of this patient population. The adoption of next-generation vascular access devices to treat this population will further increase the vascular access device market. Furthermore, the introduction of these higher-priced devices will drive an increase in average selling prices over the next 5 years. As the aging population grows, and vascular access device unit sales continue to favor more expensive devices, vascular access device revenues will rise significantly. According to a new report entitled US Markets for Vascular Access Devices 2006, the US vascular access device market generated almost $1.1 billion in revenues in 2005 and will grow over 5% annually over the next five years.

ESRD, cancer, and chronic disease are the leading maladies that require treatment with vascular access technologies. The US has the highest incidence rate of ESRD in the world and the largest population of ESRD patients. Vascular access therapies are important to this patient population, as these devices are used for hemodialysis and intravenous treatment. The large number of cancer patients in the US undergoing chemotherapy treatment also require vascular access devices. Due to the intensity and frequency of chemotherapy treatments, long-dwelling venous access devices are used. Furthermore, the treatment of age-related chronic diseases often employs vascular access devices for nutritional support and overnight or long term antibiotic treatments. The availability of both short - and long-term vascular access devices increases the applicability of vascular access devices, allowing them to be used to treat multiple maladies.

MRG’s US Markets for Vascular Access Devices 2006 report is part of its Global Markets for Vascular Access Devices series, which includes analysis on Europe and Japan. The series covers various key industry competitors, including Becton Dickinson (BDX), C. R. Bard (BCR), Arrow International (ARRO), Medex (Smith's Medical) (SMGKF), B. Braun, Medcomp, Boston Scientific (BSX), Angiodynamics (ANGO), Rita Medical Systems (RITA), Cook, Edwards Lifesciences (EW), Deltec (Smith’s Medical) (SMGKF), Kendall (Tyco Healthcare) (TYC) and Spire Biomedical (SPIR).

About Vascular Access Devices

Vascular access devices are inserted into a vein and permit administration of intermittent - or continuous-infusion solutions or medications. These devices also permit the aspiration of blood for sampling.

About Millennium Research Group

Millennium Research Group (www. MRG. net), a Decision Resources, Inc. company (www. DecisionResources. com), is a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

# # #